At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 32 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects (11038)
The University of Texas Health Science Center at San Antonio·interventional·Posted Dec 5, 2016·Updated Mar 4, 2024
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMay 2019
Primary CompletionApr 2022
Study CompletionMay 2023
TodayJul 2026
First PostedDec 5, 2016
Enrollment StartMay 23, 2019
Primary CompletionApr 30, 2022
Study CompletionMay 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.6 years ago
Interventions
Dapagliflozindrug
dapagliflozin, 10mg tablet
Placebodrug
Placebo for dapagliflozin